治疗前代谢肿瘤体积与霍奇金淋巴瘤中 CD30 CAR-T 细胞应答的关联

Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30. CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observed in a subset of patients. The objective of this study was to characterize clinical and correlative factors associated with progression-free survival (PFS) after CD30. CAR-T cell therapy.

We evaluated correlatives in 27 patients with r/r cHL treated with lymphodepletion and CD30. CAR-T cells. With a median follow-up of 9. 5 months, 17 patients (63%) progressed, with a median PFS of 352 days (95% confidence interval: 116-not reached), and 2 patients died (7%) with a median overall survival of not reached. High metabolic tumor volume (MTV, >60 mL) immediately before lymphodepletion and CD30. CAR-T cell infusion was associated with inferior PFS (log rank, P = . 02), which persisted after adjusting for lymphodepletion and CAR-T dose (log rank, P = .

01 and P = . 006, respectively). In contrast, receiving bridging therapy, response to bridging therapy, CD30. CAR-T expansion/persistence, and percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy were not associated with differences in PFS. In summary, this study reports an association between high baseline MTV immediately before lymphodepletion and CD30. CAR-T cell infusion and worse PFS in patients with r/r cHL. This trial was registered at www. clinicaltrials. gov as #NCT02690545.